150 related articles for article (PubMed ID: 27992949)
1. Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):454-464. PubMed ID: 27992949
[TBL] [Abstract][Full Text] [Related]
2. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
[TBL] [Abstract][Full Text] [Related]
5. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
van Schie RM; el Khedr N; Verhoef TI; Teichert M; Stricker BH; Hofman A; Buhre PN; Wessels JA; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; de Boer A; Maitland-van der Zee AH; Visser LE
Pharmacogenomics; 2012 Aug; 13(11):1239-45. PubMed ID: 22920394
[TBL] [Abstract][Full Text] [Related]
6. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
[TBL] [Abstract][Full Text] [Related]
8. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
[TBL] [Abstract][Full Text] [Related]
9. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
[TBL] [Abstract][Full Text] [Related]
11. Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
Furie B
N Engl J Med; 2013 Dec; 369(24):2345-6. PubMed ID: 24251364
[No Abstract] [Full Text] [Related]
12. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and coumarin dosing--recalibrating expectations.
Zineh I; Pacanowski M; Woodcock J
N Engl J Med; 2013 Dec; 369(24):2273-5. PubMed ID: 24328463
[No Abstract] [Full Text] [Related]
14. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
15. The value of pharmacogenetic testing.
Pocinki AG
JAMA Intern Med; 2015 Feb; 175(2):314. PubMed ID: 25642672
[No Abstract] [Full Text] [Related]
16. The value of pharmacogenetic testing—reply.
Kazi DS; Hlatky MA
JAMA Intern Med; 2015 Feb; 175(2):314-5. PubMed ID: 25642673
[No Abstract] [Full Text] [Related]
17. Warfarin, genes, and the (health care) environment.
Kazi DS; Hlatky MA
JAMA Intern Med; 2014 Aug; 174(8):1338-9. PubMed ID: 24934523
[No Abstract] [Full Text] [Related]
18. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
19. Genotype-guided dosing of vitamin K antagonists.
Maitland-van der Zee AH; de Boer A; Manolopoulos VG;
N Engl J Med; 2014 May; 370(18):1765-6. PubMed ID: 24804306
[No Abstract] [Full Text] [Related]
20. Genotype-guided dosing of vitamin K antagonists.
Cavallari LH; Kittles RA; Perera MA
N Engl J Med; 2014 May; 370(18):1763. PubMed ID: 24785218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
